
Thiogenesis advances TTI-0102 with new clinical trials for rare pediatric diseases, targeting 2027 data.
Thiogenesis Therapeutics announced shareholder approvals and updates on its lead drug candidate TTI-0102, aimed at treating serious pediatric diseases like nephropathic cystinosis and Leigh syndrome. The company plans to start clinical studies in lat...





